Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
It is a solid clinical trial that directly demonstrates for the first time in a well-controlled intervention study that semaglutide (a GLP-1 receptor agonist) reduces alcohol consumption in patients undergoing treatment for alcohol use disorder and obesity
Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimers disease: a phase 1b, randomized, placebo-controlled trial
While these medications are highly effective, they require ongoing use to maintain benefits, and discontinuation rates remain concerningly high
And finally, it would be interesting to see a local GCC or MENA-based company launching something similar in their own country (and then expanding it across the region)
US$ 26.41
US$ 28.77
US$ 21.70
